Publisher's Note

The December 1, 2006 article by Jones et al entitled, "Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer" (J Clin Oncol 24:5381–5387, 2006) was published online December 1, 2006 with ambiguous text that required clarification.

In the Patients and Methods section, under Study Design, the second sentence was given as:

"Patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) administered by intravenous bolus on day 1 of each 21-day cycle for four cycles as adjuvant treatment after complete surgical excision of the primary tumor (Fig 1)."

While it should have read:

"Patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) administered by intravenous infusion over 30 to 60 minutes on day 1 of each 21-day cycle for four cycles as adjuvant treatment after complete surgical excision of the primary tumor (Fig 1)."

In the Patients and Methods section, under Treatment, the fourth sentence was given as:

"AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) was administered by intravenous bolus on day 1 of each 21-day cycle."

While it should have read:

"AC (60 and 600 mg/m2, respectively) or TC (75 and 600 mg/m2, respectively) was administered by intravenous infusion over 30 to 60 minutes on day 1 of each 21-day cycle."

These corrections have been made as of April 6, 2007.